title: Loss of Rassf1a cooperates with Apc(Min) to accelerate intestinal tumourigenesis.
abstract: Promoter methylation of the RAS-association domain family 1, isoform A gene (RASSF1A) is one of the most frequent events found in human tumours. In this study we set out to test the hypothesis that loss of Rassf1a can cooperate with inactivation of the adenomatous polyposis coli (Apc) gene to accelerate intestinal tumourigenesis using the Apc-Min (Apc(Min/+)) mouse model, as mutational or deletional inactivation of APC is a frequent early event in the genesis of intestinal cancer. Further, loss of RASSF1A has also been reported to occur in premalignant adenomas of the bowel. RASSF1A has been implicated in an array of pivotal cellular processes, including regulation of the cell cycle, apoptosis, microtubule stability and most recently in the beta-catenin signalling pathway. By interbreeding isoform specific Rassf1a knockout mice with Apc(+/Min) mice, we showed that loss of Rassf1a results in a significant increase in adenomas of the small intestine and accelerated intestinal tumourigenesis leading to the earlier death of adenocarcinoma-bearing mice and decreased overall survival. Comparative genomic hybridization of adenomas from Rassf1a(-/-); Apc(+/Min) mice revealed no evidence of aneuploidy or gross chromosomal instability (no difference to adenomas from Rassf1a(+/+); Apc(+/Min) mice). Immunohistochemical analysis of adenomas revealed increased nuclear beta-catenin accumulation in adenomas from Rassf1a(-/-); Apc(+/Min) mice, compared to those from Rassf1a(+/+); Apc(+/Min) mice, but no differences in proliferation marker (Ki67) staining patterns. Collectively these data demonstrate cooperation between inactivation of Rassf1a and Apc resulting in accelerated intestinal tumourigenesis, with adenomas showing increased nuclear accumulation of beta-catenin, supporting a mechanistic link via loss of the known interaction of Rassf1 with beta-TrCP that usually mediates degradation of beta-catenin.
authors.affiliation: Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, UK. lvdw@sanger.ac.uk
authors.forename: L
authors.initials: L
authors.lastname: van der Weyden
authors.forename: M J
authors.initials: MJ
authors.lastname: Arends
authors.forename: O M
authors.initials: OM
authors.lastname: Dovey
authors.forename: H L
authors.initials: HL
authors.lastname: Harrison
authors.forename: G
authors.initials: G
authors.lastname: Lefebvre
authors.forename: N
authors.initials: N
authors.lastname: Conte
authors.forename: F V
authors.initials: FV
authors.lastname: Gergely
authors.forename: A
authors.initials: A
authors.lastname: Bradley
authors.forename: D J
authors.initials: DJ
authors.lastname: Adams
mesh_terms: D000236:Adenoma / Q000209:etiology / Q000235:genetics; D000782:Aneuploidy; D000818:Animals; D002467:Cell Nucleus / Q000378:metabolism; D043171:Chromosomal Instability; D017491:Genes, APC; D006801:Humans; D007414:Intestinal Neoplasms / Q000209:etiology* / Q000235:genetics / Q000378:metabolism; D019394:Ki-67 Antigen / Q000032:analysis; D051379:Mice; D008810:Mice, Inbred C57BL; D015398:Signal Transduction; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000502:physiology*; D051176:beta Catenin / Q000378:metabolism
chemical_list: D019394:Ki-67 Antigen; C498355:Mki67 protein, mouse; C496882:RASSF1 protein, mouse; D025521:Tumor Suppressor Proteins; D051176:beta Catenin